Approval and listing dates of protein tyrosine kinase inhibitors
Thank you for your request dated 20 January 2022 under the Official Information Act 1982 (OIA) for information relating to Pharmac approval of protein tyrosine kinase inhibitors. You requested:
a list of dates that protein tyrosine kinase inhibitors have been approved to be funded by PHARMAC. E.g. Gefitinib was approved on 1 Aug 2012
Please see the table below for the information requested.
|Medicine||Date decision announced||Date listed|
|Palbociclib (Ibrance)||5 March 2020||1 April 2020|
|Alectinib (Alecensa)||7 October 2019||1 December 2019|
|Ruxolitinib (Jakavi)||6 September 2018||1 October 2018|
|Nilotinib (Tasigna)||9 October 2014||1 November 2014|
|Gefitinib (Iressa)||5 July 2012 [PDF, 144 KB]||1 August 2012|
|Lapatinib ditosylate (Tykerb)||1 March 2012 [PDF, 166 KB]||1 April 2012|
|Pazopanib (Votrient)||1 March 2012 [PDF, 166 KB]||1 April 2012|
|Sunitinib malate (Sutent)||28 September 2010||1 November 2010|
|Erlotinib (Tarceva)||3 September 2010 [PDF, 58 KB]||1 October 2010|
|Dasatinib (Sprycel)||30 June 2009||1 August 2009|
|Imatinib mesylate (Glivec)||November 2002||1 December 2002|
Where found, I have included a hyperlink to the related decision notification for each listed protein tyrosine kinase inhibitor medicine.
We trust that this information answers your queries.
Pharmac is making information more freely available, so we now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.